Table 2. Univariate and multivariate cox hazards analysis for OS and DFS in 180 patients with non-ESCC.
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value* | HR | 95% CI | P value* | ||
| OS | |||||||
| Gender (male vs. female) | 1.30 | 0.83–2.04 | 0.260 | ||||
| Age (≤54 vs. >54) | 1.64 | 1.04–2.60 | 0.033 | 1.44 | 0.89–2.31 | 0.137 | |
| Location (upper vs. middle vs. lower) | 1.11 | 0.80–1.55 | 0.542 | ||||
| Cancer type (SC vs. AC vs. others) | 0.73 | 0.58–0.92 | 0.008 | 0.62 | 0.48–0.79 | 0.000 | |
| TNM stage (III–IV vs. I–II) | 1.59 | 1.07–2.36 | 0.023 | 2.00 | 1.29–3.08 | 0.002 | |
| Alcohol history (yes vs. no) | 0.79 | 0.50–1.24 | 0.300 | ||||
| Treatment (SUR vs. CR vs. SUR + CR) | 0.97 | 0.73–1.29 | 0.819 | ||||
| TC (≤6.12 vs. >6.12) | 1.63 | 0.97–2.73 | 0.063 | 3.15 | 1.63–6.10 | 0.001 | |
| TG (≤1.04 vs. >1.04) | 0.55 | 0.37–0.82 | 0.003 | 0.49 | 0.29–0.83 | 0.009 | |
| HDL-C (≤0.95 vs. >0.95) | 1.76 | 1.07–2.91 | 0.027 | 1.57 | 0.77–3.21 | 0.212 | |
| LDL-C (≤3.58 vs. >3.58) | 0.62 | 0.41–0.94 | 0.026 | 0.60 | 0.31–1.17 | 0.133 | |
| APOAI (≤1.39 vs. >1.39) | 0.85 | 0.51–1.41 | 0.528 | ||||
| APOB (≤0.92 vs. >0.92) | 0.54 | 0.36–0.81 | 0.003 | 0.72 | 0.43–1.21 | 0.218 | |
| AI (<4 vs. ≥4) | 0.64 | 0.41–0.99 | 0.044 | 1.08 | 0.47–2.51 | 0.851 | |
| THR (≤1.10 vs. >1.10) | 0.64 | 0.42–0.96 | 0.033 | 1.75 | 3.64–0.84 | 0.136 | |
| LHR (≤3.15 vs. >3.15) | 0.53 | 0.35–0.81 | 0.003 | 0.65 | 0.31–1.36 | 0.252 | |
| BMI (<18.5 vs. 18.5–22.9 vs. ≥23.0) | 0.94 | 0.71–1.25 | 0.662 | ||||
| DFS | |||||||
| Gender (male vs. female) | 1.14 | 0.74–1.76 | 0.559 | ||||
| Age (≤54 vs. >54) | 1.30 | 0.86–1.97 | 0.210 | ||||
| Location (upper vs. middle vs. lower) | 1.12 | 0.82–1.54 | 0.483 | ||||
| Cancer type (SC vs. AC vs. Others) | 0.81 | 0.65–1.00 | 0.054 | 0.67 | 0.53–0.85 | 0.001 | |
| TNM stage (III–IV vs. I–II) | 1.72 | 1.18–2.50 | 0.005 | 2.23 | 1.47–3.39 | 0.000 | |
| Alcohol history (yes vs. no) | 0.88 | 0.58–1.34 | 0.551 | ||||
| Treatment (SUR vs. CR vs. SUR + CR) | 0.88 | 0.67–1.16 | 0.373 | ||||
| TC (≤6.12 vs. >6.12) | 1.56 | 0.96–2.54 | 0.073 | 3.22 | 1.71–6.06 | 0.000 | |
| TG (≤1.04 vs. >1.04) | 0.51 | 0.35–0.74 | 0.000 | 0.48 | 0.29–0.79 | 0.004 | |
| HDL-C (≤0.95 vs. >0.95) | 1.82 | 1.13–2.92 | 0.014 | 1.81 | 0.93–3.54 | 0.082 | |
| LDL-C (≤3.58 vs. >3.58) | 0.64 | 0.43–0.95 | 0.038 | 0.53 | 0.28–0.99 | 0.045 | |
| APOAI (≤1.39 vs. >1.39) | 1.02 | 0.64–1.61 | 0.941 | ||||
| APOB (≤0.92 vs. >0.92) | 0.59 | 0.41–0.87 | 0.008 | 0.86 | 0.52–1.40 | 0.537 | |
| AI (<4 vs. ≥4) | 0.62 | 0.41–0.94 | 0.025 | 0.95 | 0.44–2.04 | 0.894 | |
| THR (≤1.10 vs. >1.10) | 0.60 | 0.41–0.89 | 0.012 | 1.73 | 0.87–3.44 | 0.118 | |
| LHR (≤3.15 vs. >3.15) | 0.54 | 0.36–0.81 | 0.002 | 0.74 | 0.38–1.43 | 0.364 | |
| BMI (<18.5 vs. 18.5–22.9 vs. ≥23.0) | 1.02 | 0.78–1.34 | 0.874 | ||||
*, Cox hazard regression model. Non-ESCC, non-esophageal squamous cell carcinoma; OS, overall survival; DFS, disease-free-survival; HR, hazard ratio; 95% CI, 95% confidence interval; SC, small cell carcinoma; AC, adenocarcinoma; SUR, surgery only; CR, chemotherapy and/or radiotherapy; SUR + CR, surgery and chemotherapy and/or radiotherapy; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; APOAI, apolipoprotein A-I; APOB, apolipoprotein B; AI, atherogenic index; THR, the ratio of TC to HDL-C; LHR, the ratio of LDL-C to HDL-C.